Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
| ▸ | NR1I3 | Q14994 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.34 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1862101 | 0.86 | DRD2 (0.40) | DRD2LIPENR1I3MEN1KMT2A | |
| SCHEMBL1857730 | 0.82 | LIPE (0.38) | DRD2LIPENR1I3MEN1KMT2A | |
| SCHEMBL29986227 | 0.81 | DRD2 (0.47) | DRD2LIPENR1I3MEN1KMT2A | |
| SCHEMBL1858418 | 0.79 | RECQL (0.38) | RECQLMEN1KMT2A | |
| SCHEMBL2335054 | 0.77 | KDM1A (0.48) | DRD2RECQLBCHE | |
| SCHEMBL3661398 | 0.73 | MAPK1 (0.50) | DRD2LIPEMEN1KMT2ABCHE | |
| SCHEMBL9185817 | 0.70 | L3MBTL1 (0.42) | DRD2LIPEMEN1KMT2A | |
| SCHEMBL24620676 | 0.69 | LIPE (0.44) | DRD2LIPEMEN1KMT2A | |
| SCHEMBL18938923 | 0.69 | ABHD6 (0.44) | DRD2RECQLLIPE | |
| SCHEMBL28535451 | 0.68 | P2RX4 (0.40) | DRD2MEN1KMT2ABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947834-B2 | Substituted quinoxalines, their preparation and their therapeutical use as 11βHSD1 modulators | SANOFI-AVENTIS (FR) | 2011-05-24 | — | — | US | disclosed |
| US-20090176775-A1 | DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | SANOFI-AVENTIS (FR) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176775-A1 | DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | HSD11B1, HSD3B1, ADH1C | DRD2 595/4885RECQL 427/4885LIPE 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.